Announcement

Collapse
No announcement yet.

Lancet Respir. Dis. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Lancet Respir. Dis. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial


    Lancet Respir Med. 2019 Sep 30. pii: S2213-2600(19)30199-7. doi: 10.1016/S2213-2600(19)30199-7. [Epub ahead of print] Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.

    Beigel JH1, Aga E2, Elie-Turenne MC3, Cho J4, Tebas P5, Clark CL6, Metcalf JP7, Ozment C8, Raviprakash K9, Beeler J10, Holley HP Jr10, Warner S11, Chorley C10, Lane HC12, Hughes MD2, Davey RT Jr12; IRC005 Study Team.
    Collaborators (41)

    Author information

    1 National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. Electronic address: jbeigel@niaid.nih.gov. 2 Harvard TH Chan School of Public Health, Boston, MA, USA. 3 University of Florida, Gainesville, FL, USA. 4 Massachusetts General Hospital, Boston, MA, USA. 5 University of Pennsylvania, Philadelphia, PA, USA. 6 Beaumont Hospital-Royal Oak, Royal Oak, MI, USA. 7 University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 8 Duke University Medical Center, Durham, NC, USA. 9 Naval Medical Research Center, Silver Spring, MD, USA. 10 Leidos Biomedical Research, Frederick, MD, USA. 11 Social & Scientific Systems, Silver Spring, MD, USA. 12 National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.

    Abstract

    BACKGROUND:

    Infection with influenza virus causes substantial morbidity and mortality globally, although antiviral treatments are available. Previous studies have suggested that anti-influenza immune plasma could be beneficial as treatment, but they were not designed as randomised, blinded, placebo-controlled trials. Therefore, we aimed to prospectively evaluate the clinical efficacy of high-titre immune plasma compared with standard low-titre plasma to improve outcomes in patients with severe influenza A infection.
    METHODS:

    We did this randomised, double-blind, phase 3 trial at 41 US medical centres to assess the efficacy of high-titre anti-influenza plasma (haemagglutination inhibition antibody titre ≥1:80) compared with low-titre plasma (≤1:10). Children and adults with PCR-confirmed influenza A infection, a National Early Warning score of 3 or greater, and onset of illness within 6 days before randomisation were eligible. Patients were randomly assigned (2:1) using an interactive web response system to receive either two units (or paediatric equivalent) of high-titre plasma (high-titre group) or low-titre plasma (low-titre group), and were followed up for 28 days from randomisation. High-titre and low-titre plasma had the same appearance. Randomisation was stratified by severity (in intensive care unit, not in intensive care but requiring supplemental oxygen, or not in intensive care and not requiring supplemental oxygen) and age (<18 years and ≥18 years). All participants, site staff, and the study team were masked to treatment allocation until after the final database lock. The primary endpoint was clinical status assessed by a six-point ordinal scale on day 7 (death, in intensive care, hospitalised but requiring supplemental oxygen, hospitalised not requiring supplemental oxygen, discharged but unable to resume normal activities, and discharged with full resumption of normal activities) analysed in a proportional odds model (an odds ratio [OR] >1 indicates improvement in clinical status across all categories for the high-titre vs the low-titre group). The primary analysis was done in the intention-to-treat population, excluding two participants who did not receive plasma. This trial is registered with ClinicalTrials.gov, NCT02572817.
    FINDINGS:

    Participants were recruited between Jan 26, 2016, and April 19, 2018. Of 200 participants enrolled (177 adults and 23 children), 140 met the criteria for randomisation and were assigned to the high-titre group (n=92) or to the control low-titre group (n=48). One participant from each group did not receive plasma. At baseline, 60 (43%) of 138 participants were in intensive care and 55 (71%) of 78 participants who were not in intensive care required oxygen. 93% of planned plasma infusions were completed. The study was terminated in July, 2018, when independent efficacy analysis showed low conditional power to detect an effect of high-titre plasma even if full accrual (150 participants) was achieved. The proportional OR for improved clinical status on day 7 was 122 (95% CI 065-229, p=054). 47 (34%) of 138 participants experienced 88 serious adverse events: 32 (35%) with 60 events in the high-titre group and 15 (32%) with 28 events in the low-titre group. The most common serious adverse events were acute respiratory distress syndrome (ARDS; four [4%] vs two [4%]), allergic transfusion reactions (two [2%] vs two [4%]), and respiratory distress (three [3%] vs none). 65 (47%) participants experienced 183 adverse events: 42 (46%) with 126 events in the high-titre group and 23 (49%) with 57 events in the low-titre group. The most common adverse events were anaemia (four [3%] vs two [4%]) and ARDS (four [3%] vs three [5%]). Ten patients died during the study (six [7%] in the high-titre group vs four [9%] in the low-titre group, p=073). The most common cause of death was worsening of acute respiratory distress syndrome (two [2%] vs two [4%] patients).
    INTERPRETATION:

    High-titre anti-influenza plasma conferred no significant benefit over non-immune plasma. Although our study did not have the precision to rule out a small, clinically relevant effect, the benefit is insufficient to justify the use of immune plasma for treating patients with severe influenza A.
    FUNDING:

    National Institute of Allergy and Infectious Diseases of the National Institutes of Health (Bethesda, MD, USA).
    Copyright 2019 Elsevier Ltd. All rights reserved.


    PMID: 31582360 DOI: 10.1016/S2213-2600(19)30199-7


  • #2

    Lancet Respir Med. 2019 Sep 30. pii: S2213-2600(19)30265-6. doi: 10.1016/S2213-2600(19)30265-6. [Epub ahead of print] Passive immunity for the treatment of influenza: quality not quantity.

    Kanjilal S1, Mina MJ2.
    Author information

    1 Department of Population Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 2 Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Center for Communicable Disease Dynamics, Department of Epidemiology and Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA. Electronic address: mmina@hsph.harvard.edu.

    PMID: 31582359 DOI: 10.1016/S2213-2600(19)30265-6


    Comment

    Working...
    X